



Onsite Poster Session

Group #	Time	Category	Submission No.	First Name	Last Name	Country	Title of Abstract	
Group 1	16:50-17:20 6min. x 5	Systemic Chemotherapy & Oncology 1	10069	Issei	Saeki	Japan	Characteristic of HCC Patients Achieving Clinical Complete Response Treated with Atezolizumab plus Bevacizumab	
			10057	Takanori	Mukozu	Japan	Usefulness of IL-6 as a Therapeutic Response Predictor in Atezolizumab + Bevacizumab Combination Therapy for Hepatocellular Carcinoma	
			10076	Shuntaro	Obi	Japan	Atezolizumab + Bevacizumab Post-Treatment Strategies and Outcomes	
			10027	Akihiro	Deguchi	Japan	Treatment Outcomes of ABC Conversion Therapy at Our Hospital	
			10005	Fujimasa	Tada	Japan	Clinical Features of Proteinuria During Atezolizumab plus Bevacizumab Treatment	
	17:20-17:50 6 min. x 5	Systemic Chemotherapy & Oncology 2	10030	Takashi	Tanaka	Japan	Therapeutic Efficacy of Conversion Therapy after Systemic Chemotherapy for Patients with Unresectable Hepatocellular Carcinoma	
			10053	Kei	Amioka	Japan	The Impact of Bevacizumab Withdrawal on Prognosis in Atezolizumab + Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma	
			10107	Kazuki	Maesaka	Japan	Clinical Factors Associated with the Therapeutic Efficacy of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: A Multicenter Prospective Observational Study	
			10098	Takuya	Adachi	Japan	Proangiogenic Cytokines are Useful Prognostic Markers for the Advanced Hepatocellular Carcinoma Patients with Atezolizumab plus Bevacizumab Treatment	
			10050	Masashi	Fujita	Japan	Role of Prognostic Nutritional Index in Predicting Survival during Atezolizumab plus Bevacizumab Treatment in Unresectable Hepatocellular Carcinoma: A Multicenter Study in Tohoku, Japan	
Group 2	16:50-17:20 6 min. x 5	Systemic Chemotherapy & Oncology 3	10148	Kaori	Matsumoto	Japan	Immune-related Adverse Event Occurrence and Treatment Response to Immune Checkpoint Inhibitors in Patients with Gastrointestinal Cancer; Using All Organ Cancers as the Denominator	
			10080	Hironao	Okubo	Japan	Serum Aldolase Predicts Dose Reduction or Interruption of Cabozantinib in Patients with Hepatocellular Carcinoma	
			10142	Jooho	Lee	Korea	The Safety and Efficacy of Combination Immunotherapy of TACE (Transarterial-chemoembolization) and Autologous Natural Killer Cells in Patients with Hepatocellular Carcinoma	
			10071	Kei	Endo	Japan	Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab	
			10058	Hideki	Nagumo	Japan	Effect of Atezolizumab plus Bevacizumab Combination Therapy on Skeletal Muscle Mass and Cardiac Function by Age in Patients with Hepatocellular Carcinoma	
	17:20-17:44 6 min. x 4	TACE, HAIC, Imaging, Radiation	10088	Shuntaro	Obi	Japan	Indications for Arterial Infusion Chemotherapy from the Atezolizumab + Bevacizumab (ATZ+BEV) GTO Cohort- HAIC is Always the Last Line of Defense-	
			10075	Yasuhide	Motoyoshi	Japan	Long-term Prognosis of Stereotactic Body Radiotherapy Versus Radiofrequency Ablation in Patients with Small Hepatocellular Carcinoma Evaluated by Hepatic Reserve, Single-center Study	
			10106	Kento	Imajo	Japan	Comparison of Diagnostic Accuracy between Fibroscan 630 and MR Elastography for Diagnosing Esophagogastric Varices by Measuring Splenic Stiffness	
			10102	Takashi	Nishimura	Japan	The Diagnostic Ability for Microvascular Invasion Using Contrast Enhanced Ultrasonography	
Group 3	16:50-17:14 6 min. x 4	Basic Science & Pathology 1	10044	Kana	Tsutsui	Japan	Clinicopathological Characteristics and Molecular Analysis of Lymphocyte-rich HCC	
			10101	Hirayuki	Enomoto	Japan	Identification of the Possible Target Genes of Hepatoma-derived Growth Factor in Hepatoma Cells	
			10085	Shuntaro	Obi	Japan	Differential Diagnosis of Intrahepatic Metastasis (IM) and Multicentric Carcinogenesis (MC) - How Close can Clinical Indicators Get to the Genome?	
			10087	Shuntaro	Obi	Japan	Differential Diagnosis of IM and MC by Comprehensive Genomic Profiling (CGP) Changes Treatment Strategies	
			10081	Daisuke	Taguchi	Japan	High-fat Diet Promotes Hepatic Fibrosis and Tumorigenesis in a Rat Cirrhosis Model	
	17:14-17:38 6 min. x 4	Basic Science & Pathology 2	10049	J.S	Junya Suzuki	Japan	Dual Angiotensin II Receptor and Nephrysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation	
			10018	Shinya	Sato	Japan	A Novel Hepatitis Delta Virus (HDV) in Vitro Carcinogenesis Model	
			10065	Katsuya	Toshida	Japan	Impact of TIGAR on Malignant Activity and Resistance to Ferroptosis in Intrahepatic Cholangiocarcinoma	
Group 4	16:50-17:14 6min. X 4	Basic Science & Pathology 3	10054	Yoshinari	Asaoka	Japan	Investigation of the Association between Receptor Tyrosine Kinase Expression and Genetic Variation Using TCGA HCC Data	
			10014	Satoshi	Iwai	Japan	Glucagon-like Peptide-1 Receptor Agonist, Semaglutide Attenuates Chronic Liver Disease-induced Skeletal Muscle Atrophy in Diabetic Mice	
			10061	Ekta	Yadav	India	In Vitro and in Vivo Antitumor Effect of Biofabricated Silver Nanoparticles of Caffeic Acid against Hepatocarcinogenesis by Upregulation of Bax/Bcl2	
			10060	Pankajkumar	Yadav	India	Development and Assessment of a Novel Self Nano Emulsifying Formulation of Furosemide: A Drug Employed in Treating Portal Hypertension	
			10024	Yoshiko	Fukunishi	Japan	Clinical Usefulness of Tumor Markers AFP, L3, and DCP for Treatment of Hepatocellular Carcinoma	
	17:14-17:38 6min. x4	Tumor Markers & Biochemistry	10052	Batchimeg	Batbaatar	Mongolia	Evaluation of Glypican-3 Protein in the Tissues of Hepatocellular Carcinoma by Tissue Microarray	
			10066	Katsuya	Nagaoka	Japan	Diagnostic Marker of Mitochondrial Dysfunction, AREG, is Associated with Tumor Size in Hepatocellular Carcinoma	
			10002	Glenn	Oyong	Philippines	Andrographolides Regulate c-Myc Stability and Demonstrate Cytotoxic and Genotoxic Activity in CD133+ Multi-drug Resistant Hepatocellular Carcinoma Cells via Small Molecule 20S Proteasome Activation	
Group 5	16:50-17:20 6min. x5	Surgery & Transplantation	10035	Hidetake	Amemiya	Japan	Prognosis of the Patients with Multiple Hepatocellular Carcinoma who Underwent Initial Liver Resection	
			10113	Alzhraa	Alkhatib	Egypt	Impact of Justifying MELD Score Exception by MELD-ALBI Selection on the Outcome of HCC Transplantation	
			10092	Masayasu	Aikawa	Japan	Usefulness of Laparoscopic Liver Resection for Patients with Ruptured Hepatocellular Carcinoma	
			10036	Yukihiro	Watanabe	Japan	Influence of Child-Pugh B7 and B8/9 Cirrhosis on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study	
			10146	Kenichiro	Takase	Japan	Efficacy and Safeness of Polyglycolic Acid Felt with Fibrin Glue at the Liver Cut Surface for Prevention of Postoperative Bile Leakage in Laparoscopic Liver Resection	
	17:20-17:44 6min. x4	Liver Cirrhosis & Sarcopenia	10037	Shohei	Asada	Japan	VWF/ADAMT13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis	
			10040	Tadashi	Namisaki	Japan	Diagnostic Markers for Portal Vein Thrombosis in Patients with Cirrhosis PVT	
			10004	Atsushi	Hiraoka	Japan	The Geriatric Nutritional Risk Index is a Useful Predictor of Muscle Volume Loss Regardless of Gender	
			10131	Masatsugu	Ohara	Japan	Coexistence of Muscle Atrophy and High Subcutaneous Adipose Tissue Predicts Poor Prognosis in Hepatocellular Carcinoma	
Group 6	16:50-17:14 6min. x4	Hepatitis C	10095	Hiroki	Ono	Japan	A Novel Formula Used for Predicting Hepatocellular Carcinoma after the Achievement of SVR by DAAs in Patients with Chronic Hepatitis C	
			10074	Shuntaro	Obi	Japan	Hepatic Steatosis is a Risk Factor for All-organ Carcinogenesis in Post-SVR Patients	
			10082	Shuntaro	Obi	Japan	Surveillance should Continue after SVR-Carcinogenesis Continues to Increase in a Linear Fashion-	
			10084	Shuntaro	Obi	Japan	Continued Surveillance after SVR Yields a Prognosis Equivalent to the Standardized Mortality Ratio (SMR)	
			10103	JI HOON	KIM	Korea	High HBV DNA Level Increase the Risk of Tumor Recurrence after Surgical Resection or Ablative Therapy in Patients with HBV related Hepatocellular Carcinoma	
	17:14-17:38 6min. x4	Hepatitis C, Hepatitis B	10020	Eiichi	Ogawa	Japan	Four-year Safety and Effectiveness of Tenofovir Alafenamide in Treatment-experienced Patients with Chronic Hepatitis B	
			10123	Dexton	Johns	India	The Genotypic Association of Hepatitis C Associated Oral Lichen Planus and Its Response to Direct Acting Antivirals- A Case Series	
			10034	P.	Lamichhane	Nepal	Directly Acting Antivirals Improve Insulin Resistance in Non-diabetic Patients with Hepatitis C: A Meta-analysis	
Group 7	16:50-17:14 6min. x4	NASH/ NAFLD & Genetic/ Metabolic Disease	10039	Takuya	Wada	Japan	Favorable Liver and Skeletal Muscle Changes in Patients with NAFLD and Type 2 Diabetes Receiving GLP-1 Receptor Agonist	
			10043	A.	Agrawal	Nepal	Effects of SGLT2 Inhibitors on Liver Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease and Type 2 Diabetes: A Meta-analysis	
			10079	Fang Yu	Hsu	Taiwan	Effects of Lanifibranor on High-Fat Diet-Induced-Nonalcoholic Fatty Liver Disease and Associated Mood Disorder in Mice	
			10025	Akihiko	Shibamoto	Japan	Vitamin D Deficiency Exacerbates Alcohol-related Liver Injury via Gut Barrier Disruption and Hepatic Overload of Endotoxin	
			10047	Emi	Yanagihara	Japan	Clinical Features Related to the Prognosis of Patients with Ruptured Hepatocellular Carcinoma as Initial Symptom	
	17:14-17:32 6min. x3	Others 1	10070	Kensuke	Naruto	Japan	The Clinical Results of Switching from Zoledronic Acid Hydrate to Denosumab for Bone Metastasis of Hepatocellular Carcinoma, Single-center Simple Open-labeled Prospective Interventional Trial	
			10122	Dexton	Johns	India	Health Related Quality of Life of Hepatocellular Carcinoma Metastasis to Oral Cavity - A Systematic Review	
Group 8	16:50-17:14 6min. x4	Others 2	10055	Kazumichi	Abe	Japan	Long-Term Outcomes and Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis Complicated with CREST Syndrome	
			10007	Hideko	Ohama	Japan	Prediction of Recurrence after Curative Treatment for Hepatocellular Carcinoma Using aMAP Risk Score	
			10133	Yosuke	Hirotsu	Japan	Journey and Evolution of Comprehensive Genomic Analysis: Integrating Panel Sequencing to Expert Panel Implementation	
			10013	Hiroyuki	Okuyama	Japan	Experience of Comprehensive Cancer Genome Profiling Test in Intrahepatic Cholangiocarcinoma in Our Institution	